 |
|
|
| |
The SPARTAN Study: A Pilot Study to Assess the Safety and Efficacy of an Investigational NRTI- and RTV-Sparing Regimen of Atazanavir (ATV) Experimental Dose of 300mg BID plus Raltegravir (RAL) 400mg BID (ATV+RAL) in Treatment-Naïve HIV-Infected Subjects
|
| |
| |
Reported by Jules Levin
18th Intl AIDS Conference July 18-23 2010 Vienna Austria
from Jules: the presenter announced that BMS had stopped the study at 24 weeks apparently due to hyperbilirubinemas and RAL resistance. In clinical private some clinicians use this regimen for certain patients and hyperbilirubinemias tend to decline in time. In the future it is expected that GSK572 will be studied in a once daily regimen with boosted Reyataz, nuke sparing
Michael J. Kozal, MD1, Sergio Lupo, MD2, Edwin DeJesus, MD3, Jean-Michel Molina, MD4, Cheryl McDonald, MD5, Francois Raffi, MD6,Jorge Benetucci, MD7, Marco Mancini, BS8, Rong Yang, PhD8, Victoria Wirtz, MS8, Lisa Percival, MS8, Jenny Zhang, MD, PhD8, Li Zhu, PhD8, Awny Farajallah, MD8, Bach-Yen Nguyen, MD9, Randi Leavitt, MD9, Donnie McGrath, MD, MPH8 and Max Lataillade DO, MPH8 for the SPARTAN study team.
1Yale University School of Medicine & VA CT, New Haven, CT, USA, 2Instituto CAICI, Rosario, Argentina, 3Orlando Immunology Center, Orlando, FL, USA, 4Dept. of Infectious Diseases, Saint-Louis Hospital and University of Paris Diderot Paris 7, Paris, France, 5Tarrant County Infectious Disease Association, Fort Worth, TX, USA , 6University
Hospital, Nantes, France, 7FUNDAI (Fundacion de ayuda al Inmunodeficiente) and University of Buenos Aires, Buenos Aires, Argentina, 8Bristol-Myers Squibb, Global Development and Medical Affairs, USA, 9Merck Research Laboratories, North Wales, PA, USA.
|
| |
|
|
|
|
|
